Resveratrol derivatives as potential treatments for Alzheimer's and Parkinson's disease

Neurodegenerative diseases are characterized by the progressive loss of neurons in different regions of the nervous system. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, and the symptoms associated with these pathologies are closely rela...

Descripción completa

Detalles Bibliográficos
Autores: Arbo, Bruno Dutra, Miral, Corinne André, Nasser, Raif Gregorio Nasre, Schimith, Lucia Emanueli, Santos, Michele Goulart dos, Silva, Dennis Guilherme da Costa, Baisch, Ana Luiza Muccillo, Hort, Mariana Appel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Brasil
Institución:Universidade Federal do Rio Grande do Sul (UFRGS)
Repositorio:Repositório Institucional da UFRGS
Idioma:inglés
OAI Identifier:oai:www.lume.ufrgs.br:10183/217185
Acceso en línea:http://hdl.handle.net/10183/217185
Access Level:acceso abierto
Palabra clave:Doença de Alzheimer
Doença de Parkinson
Tratamento farmacológico
Resveratrol
Neurodegenerative diseases
Neurodegeneration
Neuroprotection
Polyphenols
Stilbene
Aging
Descripción
Sumario:Neurodegenerative diseases are characterized by the progressive loss of neurons in different regions of the nervous system. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, and the symptoms associated with these pathologies are closely related to the regions that are most affected by the process of neurodegeneration. Despite their high prevalence, currently, there is no cure or disease-modifying drugs for the treatment of these conditions. In the last decades, due to the need for the development of new treatments for neurodegenerative diseases, several authors have investigated the neuroprotective actions of naturally occurring molecules, such as resveratrol. Resveratrol is a stilbene found in several plants, including grapes, blueberries, raspberries, and peanuts. Studies have shown that resveratrol presents neuroprotective actions in experimental models of AD and PD, however, its clinical application is limited due to its rapid metabolism and low bioavailability. In this context, studies have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation, methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity. Therefore, this review article aims to discuss how resveratrol derivatives could represent viable molecules in the search for new drugs for the treatment of AD and PD.